Related Experiment Video

Updated: Jun 2, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells

Soumya Jaganathan1, Peibin Yue, David C Paladino

  • 1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, United States of America.

Plos One
|May 17, 2011
PubMed

Insights

A novel nuclear complex of epidermal growth factor receptor (EGFR), Src, and Signal Transducer and Activator of Transcription (Stat)3 proteins drives pancreatic cancer by regulating c-Myc. This complex explains resistance to single-agent therapies targeting EGFR, Src, or Stat3.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Pancreatic cancer exhibits resistance to targeted therapies.
  • The epidermal growth factor receptor (EGFR), Src, and Signal Transducer and Activator of Transcription (Stat)3 pathways are implicated in cancer progression.

Purpose of the Study:

  • To investigate the nuclear presence and function of a heteromeric complex involving EGFR, Src, and Stat3 in pancreatic cancer.
  • To elucidate the role of this complex in regulating c-Myc gene expression and its implications for therapeutic resistance.

Main Methods:

  • Utilized siRNA knockdown to modulate EGFR and Src expression.
  • Employed pharmacological inhibition to target Stat3 activity.
  • Performed chromatin immunoprecipitation (ChIP) assays to assess protein-DNA interactions.
  • Analyzed c-Myc gene expression levels under various inhibition conditions.

Main Results:

  • A functional heteromeric complex of nuclear EGFR, Src, and Stat3 was identified in pancreatic cancer cells.
  • This complex remained intact upon individual knockdown of EGFR or Src, indicating inherent stability.
  • The nuclear complex directly binds to the c-Myc promoter.
  • Concurrent inhibition of EGFR/Stat3, Src/Stat3, or EGFR/Src significantly suppressed c-Myc expression, unlike single-agent inhibition.

Conclusions:

  • A novel nuclear EGFR-Src-Stat3 complex intricately regulates c-Myc transcription in pancreatic cancer.
  • This complex provides a mechanism for supporting the pancreatic cancer phenotype.
  • The findings explain the observed insensitivity of pancreatic cancer cells to therapies targeting EGFR, Src, or Stat3 individually.

More Related Videos

Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture03:42

Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture

Published on: September 27, 2024

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...